Join the 'Postherpetic Neuralgia' group to help and get support from people like you.
Postherpetic Neuralgia News
Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain
Posted 11 Mar 2018 by Drugs.com
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) – Sorrento Therapeutics, Inc. (NASDAQ:SRNE) (“Sorrento”), and its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), received approval from the U.S. Food and Drug Administration (FDA) for ZTlido (lidocaine topical system) 1.8%. ZTlido is indicated for the relief of pain associated with post-herpetic neuralgia (PHN), also referred to as pos ...
Posted 17 Oct 2017 by Drugs.com
October 12, 2017 - Pfizer Inc. (NYSE: PFE) announced today that the United States Food and Drug Administration (FDA) has approved Lyrica CR (pregabalin) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia (PHN). Lyrica CR did not receive approval for the ...
Posted 4 Jun 2015 by Drugs.com
TBD, 2015 – Even when shingles vaccination does not prevent the disease, it reduces the risk of long-term pain that can occur as a complication of the condition, according to a new study. Although the U.S. Advisory Council on Immunization Practices recommends shingles vaccination for people 60 and older, vaccination rates remain low, the researchers say. "Hopefully, this study will encourage ...
Posted 7 Jun 2012 by Drugs.com
LONDON & RESEARCH TRIANGLE PARK, N.C. & SANTA CLARA, Calif.--(BUSINESS WIRE)--Jun 7, 2012 - GlaxoSmithKline plc and XenoPort, Inc. announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults. The efficacy and safety of Horizant for the management of ...
NeurogesX Receives FDA Approval of Qutenza (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Posted 2 Dec 2009 by Drugs.com
SAN MATEO, Calif., Nov. 16 /PRNewswire-FirstCall/ – NeurogesX, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Qutenza (capsaicin) 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherpetic neuralgia (PHN), the nerve pain which can follow shingles. Qutenza delivers a synthetic form ...
Related Condition Support Groups
Related Drug Support Groups
gabapentin, Lyrica, Neurontin, clonidine, nortriptyline, pregabalin, Lidoderm, Gralise, capsaicin, view more... Horizant, Pain Doctor, gabapentin enacarbil, Capzasin, Zostrix, Capzasin-HP, ZTlido, Capzasin-P, Qutenza, Trixaicin, Sloan's Liniment, Pain-X, Drs Cream, Trixaicin HP, Lyrica CR, CidalEaze, R-Gel, Gabarone, No Pain-HP, Zostrix-HP, Zostrix Neuropathy, GNP Capsaicin, Capsin, Dolorac, Axsain, RT Capsin, Salonpas Gel-Patch, Capzasin Back and Body, Icy Hot PM, Zostrix Sports, Capsicum Oleoresin, Castiva Warming